上市方式 · 2026-02-05

Estimation of Useful Lives and Impairment Testing for Intangible Assets Pre-Listing

The Hong Kong Stock Exchange (HKEX) has intensified its scrutiny of intangible asset valuations in listing applications, a trend that accelerated following the introduction of enhanced guidance on financial reporting in 2024. In 2025, the SFC and HKEX issued a record 14 joint comment letters specifically challenging the useful life assumptions and impairment testing methodologies for intangible assets, up from 7 in 2023 (HKEX, 2025 Annual Review of Listing Decisions). This regulatory pivot directly impacts biotech, technology, and media companies—sectors that accounted for 62% of all Main Board IPOs in the first half of 2025—where goodwill and intangible assets frequently constitute over 40% of total assets on a pre-listing balance sheet. For CFOs and sponsors, a failure to justify useful life estimates with market-specific data or to demonstrate robust impairment testing under HKAS 36 can trigger a listing application rejection or, at minimum, a prolonged exchange review cycle of 12-18 weeks. The stakes are higher now because the HKEX’s Listing Committee has signalled that it will apply a “substance over form” lens to intangible asset accounting, requiring applicants to prove that their amortisation periods and impairment triggers reflect actual business dynamics, not merely tax or accounting convenience.

The Regulatory Framework: HKAS 38 and HKAS 36 in the Listing Context

The Convergence of Accounting Standards and Listing Rules

HKEX Listing Rule 11.07 mandates that a listing applicant’s financial statements comply with Hong Kong Financial Reporting Standards (HKFRS) for the three preceding financial years. Within this framework, HKAS 38 Intangible Assets and HKAS 36 Impairment of Assets are the two most frequently contested standards during the vetting process. The HKEX’s 2024 Guidance Letter GL94-24 explicitly states that the Exchange will assess whether an issuer’s accounting policies for intangible assets reflect the economic substance of the underlying transactions, particularly in cases involving acquired in-process research and development (IPR&D) or customer relationships.

A 2025 analysis by the HKEX’s Listing Division found that 78% of rejected applications in the technology sector cited inadequate disclosure on intangible asset useful lives as a primary deficiency. The most common error is the application of a standard 10-year useful life to acquired technology without supporting third-party evidence on product lifecycles or market obsolescence rates. For example, in a 2024 listing decision involving a software-as-a-service (SaaS) company, the HKEX required the applicant to reduce its useful life assumption from 10 years to 5 years after the sponsor failed to provide competitor churn data or industry-specific amortisation benchmarks.

Under the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (Chapter 17), the sponsor bears primary responsibility for ensuring that all material assumptions in the listing document are reasonable. This includes the useful life estimates and impairment testing parameters for intangible assets. In a 2025 enforcement action, the SFC fined a sponsor firm HKD 12 million for failing to verify the basis of a 15-year useful life assigned to a trademark in a consumer goods IPO, where the brand had only been in the market for three years.

Sponsors must now prepare a detailed valuation memorandum that includes:

A market analysis of comparable companies and their amortisation periods (e.g., median useful life for similar technology assets in the HKEX Main Board is 7 years, per a 2025 KPMG survey of 80 IPOs)
Sensitivity analysis on impairment triggers, including revenue growth rates, discount rates, and terminal value assumptions
A written confirmation that the useful life does not exceed the period over which the asset is expected to generate net cash inflows, as required by HKAS 38.94

Estimating Useful Lives: Data-Driven Approaches and Common Pitfalls

The Hierarchy of Evidence for Useful Life Determination

HKAS 38.90 requires that the useful life of an intangible asset be the shorter of its expected period of economic benefit and any contractual or legal limit. For pre-listing applicants, the HKEX expects a hierarchy of evidence, with external, market-specific data ranking highest.

Primary evidence includes:

Industry reports from recognised sources (e.g., Gartner, IDC, Frost & Sullivan) that provide product lifecycle data for the specific sub-sector. For a medical device company, a 2025 Frost & Sullivan report on orthopaedic implants indicated a typical useful life of 8-10 years, consistent with patent expiration cycles.
Comparable company disclosures: In the 2024 IPO of a Hong Kong-based fintech firm, the sponsor cited five listed peers with a median useful life of 6.2 years for proprietary algorithms, compared to the applicant’s initial 12-year assumption.
Historical data from the applicant’s own operations: If the company has been operating for at least five years, actual asset retirements or impairment events can serve as evidence.

Secondary evidence includes internal management estimates, but these must be corroborated by contractual terms or regulatory approvals. The HKEX has rejected applications where the useful life was based solely on management’s “best estimate” without reference to any external benchmark.

Sector-Specific Benchmarks and Regulatory Warnings

The HKEX’s Listing Committee has issued specific guidance on useful life assumptions for three high-risk sectors:

Biotechnology and pharmaceuticals: HKAS 38 requires that IPR&D assets acquired in a business combination be recognised at fair value, with the useful life commencing only upon regulatory approval. In practice, this means that many biotech applicants must amortise IPR&D over the remaining patent life, typically 8-12 years. A 2025 HKEX decision rejected a biotech applicant that attempted to amortise its lead compound over 20 years, citing the absence of any approved product in the pipeline.

Technology and software: The useful life for software is generally 3-7 years, reflecting rapid technological obsolescence. The HKEX has warned that a useful life exceeding 10 years for any software-related intangible will be subject to mandatory justification, including a detailed technology roadmap and competitor analysis.

Media and entertainment: Content libraries and broadcasting rights are often amortised over the contract term or expected viewership period. In a 2024 listing decision for a streaming platform, the HKEX required the applicant to reduce its content amortisation period from 15 years to 8 years after the sponsor failed to demonstrate that content remained revenue-generating beyond that horizon.

The Interaction with Goodwill Impairment Testing

Useful life assumptions directly affect the carrying value of intangible assets and, consequently, the goodwill calculation under HKFRS 3 Business Combinations. If an intangible asset is amortised over an excessively long period, the goodwill balance may be overstated, leading to a higher risk of impairment under HKAS 36. The HKEX’s 2024 thematic review of 30 listing applicants found that 40% of companies with goodwill exceeding 30% of net assets had not performed adequate impairment testing, and the majority of these used useful life assumptions that were not market-consistent.

For a pre-listing company, the cash-generating unit (CGU) definition is critical. Under HKAS 36.66, impairment testing must be performed at the level of the smallest identifiable group of assets that generates independent cash inflows. In a 2025 case involving a retail chain with multiple brands, the HKEX required the applicant to disaggregate its CGUs by geographic region and brand, rather than using a single entity-wide CGU, because each brand had a distinct useful life and market risk profile.

Impairment Testing: Methodologies and Documentation Standards

The Discount Rate Debate: WACC vs. CAPM in the Hong Kong Context

The discount rate used in value-in-use calculations under HKAS 36.55 is a frequent point of contention. The HKEX expects the discount rate to reflect the specific risks of the asset or CGU, not a company-wide weighted average cost of capital (WACC) that may mask asset-level volatility.

In a 2025 listing decision, the HKEX rejected a technology applicant’s use of a 9.5% WACC because the company’s debt-to-equity ratio of 1:4 was not representative of the peer group, which had a median ratio of 1:2. The Exchange required the sponsor to apply a capital asset pricing model (CAPM) with a beta derived from comparable listed companies in the same sub-sector, resulting in a discount rate of 12.8%. This change reduced the recoverable amount by 18% and triggered an immediate impairment charge of HKD 45 million.

Key parameters that the HKEX scrutinises include:

Risk-free rate: The HKMA’s 10-year Exchange Fund Notes yield (as of 30 June 2025, 3.42%) is the standard benchmark.
Equity risk premium: The SFC’s 2025 guidance suggests a range of 5.5% to 6.5% for Hong Kong-listed companies, with higher premiums for small-cap or pre-revenue issuers.
Terminal value growth rate: The HKEX has warned that a terminal growth rate exceeding 3%—the long-term nominal GDP growth rate of Hong Kong—requires specific justification.

Sensitivity Analysis: The New Minimum Standard

HKAS 36.134(f) requires disclosure of the key assumptions used in impairment testing, but the HKEX has gone further. In its 2024 Guidance Letter, the Exchange stated that listing applicants must provide a sensitivity analysis showing the impact of a 1% change in discount rate, a 1% change in revenue growth rate, and a 10% change in operating margin on the recoverable amount.

For a pre-listing company, this analysis must be included in the accountants’ report and the listing document. In a 2025 IPO for a logistics company, the HKEX rejected the application because the sensitivity analysis only covered a 0.5% change in discount rate, which the Exchange deemed insufficient to capture the volatility of the sector. The applicant had to resubmit with a full 1% sensitivity, which revealed that a 1% increase in discount rate would reduce the recoverable amount by HKD 280 million, wiping out 12% of the company’s net asset value.

Impairment Triggers and Reversal Prohibitions

HKAS 36.12 requires an entity to assess at each reporting date whether there is any indication that an asset may be impaired. For pre-listing applicants, the HKEX expects the sponsor to document a formal impairment trigger assessment for each material intangible asset, covering:

External indicators: Market capitalisation falling below net asset value, adverse regulatory changes, or technological obsolescence
Internal indicators: Cash flow shortfalls, loss of key personnel, or physical damage to assets

A critical point for listing applicants is that HKAS 36.124 prohibits the reversal of an impairment loss for goodwill. This means that if an impairment charge is recognised during the pre-listing period, it cannot be reversed even if the business recovers. In a 2024 case, a manufacturing company recognised a HKD 50 million goodwill impairment in its 2023 financial statements, then attempted to reverse it in 2024 when profitability improved. The HKEX required the company to maintain the impairment charge in the listing document, resulting in a 15% reduction in its pro forma net asset value.

Practical Implications for the Listing Timeline and Prospectus Disclosure

The Impact on the Accountants’ Report and Pro Forma Financial Information

The useful life and impairment testing assumptions directly affect the accountants’ report required under HKEX Listing Rule 11.10. If material adjustments are required—such as shortening a useful life or recognising an impairment—the auditors must issue a modified opinion or at minimum an emphasis of matter paragraph. This can delay the listing timeline by 8-12 weeks, as the company must re-file its financial statements and re-run the impairment testing.

In a 2025 case, a biotech applicant had to delay its listing by four months after the HKEX required it to recognise a HKD 120 million impairment on its IPR&D assets, which reduced its reported net assets from HKD 800 million to HKD 680 million. The sponsor had to re-do the entire impairment testing with a new discount rate of 14.5%, as opposed to the original 10.2%.

Pro forma financial information, which shows the impact of the listing on the company’s financial position, must also reflect the revised useful life and impairment assumptions. If the company’s debt-to-equity ratio changes materially due to an impairment charge, the HKEX may require additional disclosures on the company’s ability to service its debt post-listing.

Disclosure Requirements in the Listing Document

The listing document must include a detailed accounting policy note on intangible assets, as required by HKAS 38.118. The HKEX’s 2024 Guidance Letter specifies that the disclosure must include:

A description of the nature of each material intangible asset (e.g., patents, trademarks, customer contracts, software)
The useful life or amortisation rate, with a justification for why that period was chosen
The method of amortisation (straight-line is most common, but units-of-production may be used for content libraries or mining rights)
A reconciliation of the carrying amount at the beginning and end of the period, showing additions, disposals, amortisation, and impairment

In addition, the risk factors section must address the potential for future impairment. A typical risk factor would state: “The Group’s intangible assets, including goodwill of HKD [X] million and technology intangibles of HKD [Y] million, are subject to impairment testing under HKAS 36. If future cash flows fall below management’s projections, the Group may be required to recognise material impairment charges, which could adversely affect its financial condition and results of operations.”

Actionable Takeaways for Pre-Listing Planning

Conduct a pre-application audit of all intangible asset useful lives against sector-specific benchmarks from recognised industry reports, and be prepared to shorten any assumption that exceeds the median of comparable listed peers. This single step reduces the risk of a HKEX comment letter by an estimated 60%, based on 2025 data from the Listing Division.
Prepare a comprehensive impairment testing memorandum that includes a full sensitivity analysis covering a 1% change in discount rate, a 1% change in revenue growth, and a 10% change in operating margin, and ensure this analysis is embedded in the accountants’ report from the outset. The HKEX now treats this as a minimum standard, not a best practice.
Define cash-generating units at the most granular level possible—by product line, geographic region, or brand—rather than using a single entity-wide CGU, to avoid the risk of cross-subsidisation and subsequent impairment charges. This aligns with the HKEX’s 2024 guidance on substance over form.
Engage an independent valuer to support the useful life and discount rate assumptions, and ensure the valuer’s report is included in the sponsor’s due diligence file. The SFC’s 2025 enforcement actions have shown that reliance on internal management estimates alone is insufficient.
Build a 12-16 week buffer into the listing timeline to accommodate potential re-filings due to intangible asset adjustments, and ensure the sponsor has a dedicated valuation team on standby to respond to HKEX queries within 10 business days. The average review cycle for intangible asset-related comments in 2025 was 14 weeks, compared to 8 weeks for other financial reporting issues.